ES2043808T3 - Purificacion de antigeno superficial de hepatitis b recombinante. - Google Patents

Purificacion de antigeno superficial de hepatitis b recombinante.

Info

Publication number
ES2043808T3
ES2043808T3 ES88301779T ES88301779T ES2043808T3 ES 2043808 T3 ES2043808 T3 ES 2043808T3 ES 88301779 T ES88301779 T ES 88301779T ES 88301779 T ES88301779 T ES 88301779T ES 2043808 T3 ES2043808 T3 ES 2043808T3
Authority
ES
Spain
Prior art keywords
antigen
purification
surface antigen
yeast
daltons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88301779T
Other languages
English (en)
Inventor
William M Hurni
Dennis J Kubek
William J Miller
Mark S Rienstra
Edward M Scolnick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of ES2043808T3 publication Critical patent/ES2043808T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)

Abstract

LAS PROTEINAS DE LEVADURA UNIDAS HIDROFOBAMENTE A UNA PROTEINA DESEADA O POLIPEPTIDO PRODUCIDO EN UNA LEVADURA TRANSFORMADA SE SEPARAN TRATANDO EL ANTIGENO CON UN AGENTE COOTROPICO Y CONCENTRANDO EL ANTIGENO TRATADO EN UN HAZ CAPILAR DE FIBRA HUECA QUE TIENE UNA SECCION DE PESO MOLECULAR MAYOR DE 50.000 DALTONS PERO MENOR DE 1.000.000 DALTONS. EL ANTIGENO CONCENTRADO SE FILTRA DESPUES USANDO UN AGENTE COOTROPICO PARA SEPARAR SUSTANCIALMENTE TODA LA PROTEINA DE LEVADURA QUE QUEDA.
ES88301779T 1987-03-09 1988-03-01 Purificacion de antigeno superficial de hepatitis b recombinante. Expired - Lifetime ES2043808T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2334787A 1987-03-09 1987-03-09

Publications (1)

Publication Number Publication Date
ES2043808T3 true ES2043808T3 (es) 1994-01-01

Family

ID=21814559

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88301779T Expired - Lifetime ES2043808T3 (es) 1987-03-09 1988-03-01 Purificacion de antigeno superficial de hepatitis b recombinante.

Country Status (10)

Country Link
EP (1) EP0291146B1 (es)
JP (1) JPS63270629A (es)
AT (1) ATE93891T1 (es)
AU (1) AU608813B2 (es)
CA (1) CA1304887C (es)
CY (1) CY1790A (es)
DE (1) DE3883596T2 (es)
DK (1) DK123288A (es)
ES (1) ES2043808T3 (es)
HK (1) HK48094A (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960023066A (ko) * 1994-12-10 1996-07-18 성재갑 전에스 (s) 2 펩티드 함유 비 (b) 형 간염 표면항원의 정제 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU584580B2 (en) * 1982-09-08 1989-06-01 Smith Kline - Rit Hepatitis B virus vaccine
EP0171908A3 (en) * 1984-07-11 1987-07-15 Takeda Chemical Industries, Ltd. Hepatitis b virus surface antigen and production thereof
US4895800A (en) * 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
JPS62298536A (ja) * 1986-06-17 1987-12-25 Green Cross Corp:The 生理活性物質の自動精製方法および自動精製装置
ATE91304T1 (de) * 1987-02-27 1993-07-15 Merck & Co Inc Verfahren zur herstellung des pres 1/s2/shepatitis-b-antigens aus hefe.

Also Published As

Publication number Publication date
EP0291146A2 (en) 1988-11-17
DE3883596T2 (de) 1994-02-17
EP0291146A3 (en) 1989-12-06
DE3883596D1 (de) 1993-10-07
ATE93891T1 (de) 1993-09-15
CA1304887C (en) 1992-07-07
CY1790A (en) 1995-10-20
HK48094A (en) 1994-05-20
EP0291146B1 (en) 1993-09-01
JPS63270629A (ja) 1988-11-08
DK123288A (da) 1988-09-10
AU1277888A (en) 1988-09-08
DK123288D0 (da) 1988-03-08
AU608813B2 (en) 1991-04-18

Similar Documents

Publication Publication Date Title
ATE224956T1 (de) Verfahren zur verstärkten expression von virusproteinen
ATE187775T1 (de) Verfahren zur herstellung von menschlichem serumalbumin in hefe
FI101381B1 (fi) Nukleotidisekvenssi ja menetelmä polypeptidin HSA(1-387) tuottamiseksi
ATE373010T1 (de) Gag-antigen und dessen verwendung zum nachweis von lav-infektion, sowie in immunogenen zusammensetzungen
ATE91714T1 (de) Transformation von trichoderma.
DE3587394D1 (de) Rekombinante virusproteine begleitet von lymphadenopathischem syndrom und/oder "acquired immune deficiency syndrome" (aids).
ES2052580T3 (es) Nuevas formas de factor-1 estimulante de colonias.
DE69019609D1 (de) Proteine und deren Herstellung.
ATE173275T1 (de) Von einem retrovirus aus der hiv-gruppe abgeleitete peptide und deren verwendung
ES2108681T3 (es) Expresion de la albumina del suero humano en las levaduras metilotroficas.
FI19992546A (fi) Hepatiitti B:n S- ja PreS2-proteiinien ilmentäminen metylotrofisissa hiivoissa
ATE6402T1 (de) Verfahren zur herstellung von hepatitis b oberflaechenantigen.
ES2043808T3 (es) Purificacion de antigeno superficial de hepatitis b recombinante.
IL88377A0 (en) Molecular cloning of the human interferon type 1 receptor
DE3750348D1 (de) Verfahren zur Herstellung von Peptiden, dazu zu verwendendes rekombinantes Plasmid und mit diesem Plasmid transformierte Myelomzellen.
ES2078229T3 (es) Procedimiento para la preparacion de un polipeptido similar a la motilina y su expresion.
EP0433378A4 (en) Allelic variants of -i(plasmodium falciparum) merozoite surface antigen
EP0293201A3 (en) Method of vaccination for hepatitis b virus
NZ230996A (en) Immunogenic recombinant polypeptides and their use in the production of neutralising antibodies against viral haemorrhagic septicaemia virus
PT89041A (pt) Metodo de preparacao de diagnosticos e vacinas nanbv
GB2244273A (en) Allelic variants of plasmodium falciparum merozoite surface antigen.
MY106940A (en) Allelic variants of plasmodium falciparum merozoite surface antigen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 291146

Country of ref document: ES